Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.390
-0.050 (-3.47%)
At close: Oct 8, 2025, 4:00 PM EDT
1.380
-0.010 (-0.72%)
After-hours: Oct 8, 2025, 5:42 PM EDT
Rein Therapeutics Stock Forecast
RNTX's stock price has decreased by -57.49% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Rein Therapeutics stock has a target of 10, which predicts a 619.42% increase from the current stock price of 1.39.
Price Target: $10 (+619.42%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rein Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 |
|---|---|---|
| Strong Buy | 0 | 1 |
| Buy | 0 | 0 |
| Hold | 1 | 1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +619.42% | Sep 22, 2025 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 19, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.94
from -3.51
EPS Next Year
-0.55
from -0.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.97 | -0.57 | |
| Avg | -0.94 | -0.55 | |
| Low | -0.90 | -0.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.